Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
HONG KONG, Jun 9, 2025 - (ACN Newswire) - At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled